Compare Johnson & Johnson (JNJ) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Tapestry, Inc. — how do they compare? Johnson & Johnson trades at $250.15 (market cap $598.96B), while Tapestry, Inc. trades at $140.88 (market cap $28.51B). The key difference: Johnson & Johnson is far larger — about 21× Tapestry, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | TPR | |
|---|---|---|
Market Cap | $598.96B | $28.51B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $160.49 |
52-Week Low | $164.36 | $95.69 |
Enterprise Value | $631.90B | $31.37B |
Dividend Yield | 2.15% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
TPR trades at $140.45, down 0.71% on the day, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 76.18% gross margin and 55.74% ROE, though net income margin fell to 8.44% in 2025. Recent quarters have consistently beaten EPS estimates, and analyst consensus is strongly bullish with a $183.88 price target. Cash flow trends are volatile, with 2025 showing a net outflow of $5.02B due to financing activities.
Outlook remains positive driven by earnings beats and digital growth, but high valuation ratios (P/E 43.13) and debt levels pose risks. The stock offers 31% upside to consensus target, supported by institutional buy ratings and strong brand momentum in luxury retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
